- Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD) — Recruiting • Respiratory / COPD / Asthma • NCT07192705.
- Sponsor: University College, London.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
Nontuberculous mycobacteria (NTM) are environmental organisms found in soil and water. The majority do not cause human disease. When they do, this is mostly as a chronic lung infection in people with long-term lung problems such as chronic obstructive pulmonary disease (COPD), bronchiectasis, or cystic fibrosis. The number of people with NTM pulmonary disease (PD) is increasing, and its management can be complex, requiring prolonged treatment with multiple, often toxic, drugs in someone who may already be frail. Non-drug approaches, such as airway clearance techniques, structured exercise, nutritional support and…
- : - Age: 18 years or older, able to provide informed consent. NTM-PD Group: * Participants will be adults diagnosed with confirmed NTM-PD based on the British Thoracic Society (BTS) guidelines. * The participant should not be on any antimicrobial therapy (at least two weeks before participation) and should not have previously received or be currently on antimicrobial therapy for NTM-PD. * BTS guidelines: * Clinical (both required): * Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution CT scan that shows multifocal bronchiectasis with multiple small nodules. * Appropriate exclusion of other diagnoses. * Microbiological: * A minimum of two positive expectorated sputum culture results of the same NTM species from samples collected on separate days within 12 months before recruitment. OR * Positive culture results from at least one bronchial wash or lavage. OR * Transbronchial or other lung biopsy with mycobacterial histopathological features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathological features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture-positive for NTM. Bronchiectasis Group: * Diagnosed with bronchiectasis, as confirmed in medical records based on clinical assessment, and radiological findings.…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.